New mRNA vaccine shows promise against common virus that can harm newborns

NCT ID NCT04232280

Completed ⭐️ VACCINE ⭐️ Sponsor: ModernaTX, Inc. Source: ClinicalTrials.gov ↗

First seen May 16, 2026 · Last updated May 19, 2026 · Updated 1 time

Summary

This study tested an experimental mRNA vaccine (mRNA-1647) to prevent cytomegalovirus (CMV) infection in 315 healthy adults aged 18 to 40. Participants received one of three doses of the vaccine or a placebo. The main goals were to check safety and measure the body's immune response. Results will help determine the best dose for future studies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Alliance for Multispecialty Research

Lexington, Kentucky, 40509, United States
Aventiv Research Inc

Columbus, Ohio, 43213-6523, United States
Benchmark Research

Sacramento, California, 95864, United States
Crossroads Clinical Research

Victoria, Texas, 77901, United States
Foothill Family Clinic

Salt Lake City, Utah, 84109, United States
Foothill Family Clinic-South Clinic

Salt Lake City, Utah, 84121, United States
Johnson County Clin-Trials

Lenexa, Kansas, 66219, United States
Optimal Research

Peoria, Illinois, 61614, United States
Tekton Research Inc

Austin, Texas, 78745, United States

Conditions

Explore the condition pages connected to this study.

CYTOMEGALOVIRUS INFECTION